Qyuns Therapeutics Co., Ltd. (HKG: 2509)

Market Cap	5.74B
Revenue (ttm)	64.12M
Net Income (ttm)	-453.22M
Shares Out	222.07M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	105,600
Open	25.50
Previous Close	25.85
Day's Range	24.30 - 25.80
52-Week Range	14.00 - 30.55
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 15, 2024

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People’s Republic of China. The company’s lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Rα, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 331
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2509

Financial Performance

In 2023, Qyuns Therapeutics's revenue was 14.75 million, an increase of 52.67% compared to the previous year's 9.66 million. Losses were -507.75 million, 70.3% more than in 2022.

Financial numbers in CNY